Survival Outcomes of Selinexor-Containing Triplets in Myeloma

Shebli Atrash, MD, of the Atrium Health Levine Cancer Institute, discusses the study, “Real-world treatment patterns and survival outcomes of patients with relapsed or refractory multiple myeloma treated with selinexor-containing triplet-based regimens,” presented at the 21st International Myeloma Society Annual Meeting.

The study evaluated four selinexor triplet combinations: selinexor, dexamethasone, and either bortezomib (XVd), carfilzomib (XKd), daratumumab (XDd), or pomalidomide (XPd).

The median overall survival was 14.7 months for the overall cohort and 14.4 months for patients who were triple-class exposed.

“[This] gives us good insight about the importance of using all the approved drugs that we have in hand to improve patient outcomes,” Dr. Atrash said. “Selinexor seems to reactivate or repotentiate activity of previously used antimyeloma treatments for patients who have refractory myeloma, and it seems to be used successfully to bridge to another treatment option for patients who are slated to get bispecific treatment.”